IN HB1345

Legislative council is urged to assign the interim study committee on public health, behavioral health, and human services to study prescription drug price transparency by drug manufacturers in Indiana.

Study should examine the effect that significant price increases on established drugs and high costs of new drugs have on health service delivery and consumers' ability to access and afford prescription drug treatments.

Study should assess how increased prescription drug prices impact state agencies administering Medicaid, the children's health insurance program, and the healthy Indiana plan.

Study should evaluate the effect of substantial drug price increases on costs to state and local governments providing prescription drug treatments to government employees, senior citizens, inmates, individuals with disabilities, and others needing assistance.

Study should identify best means to provide transparency on prescription drug price increases to help state and local governments, benefit managers, and consumers manage budgets and reduce costs; provision expires January 1, 2019.